Welcome to our dedicated page for ORGANIGRAM GLOBAL SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organigram Global Inc. filings document the disclosures of a Canadian cannabis company listed on Nasdaq and the TSX. Its Form 6-K reports furnish news releases, material change reports, shareholder meeting materials, proxy forms and other exhibits covering operating results, product announcements, material agreements and corporate events.
The company’s regulatory record includes disclosure about licensed cultivation and processing, adult-use cannabis brands, cannabinoid beverages, the FAST nanoemulsion technology platform, Health Canada regulation, capital-structure matters, shareholder voting, board and committee governance, and director and executive compensation practices.
Organigram Global Inc. reported strong growth for the quarter ended December 31, 2025, with net revenue rising to $63,538 from $42,730 a year earlier, driven by higher Canadian recreational and international sales and contributions from the Motif acquisition.
Gross margin before fair value adjustments improved to $23,517, a 37% margin, while adjusted gross margin reached $23,855 or 38%. Adjusted EBITDA increased to $5,265 from $1,410, and net income swung to a profit of $19,969 versus a prior-year loss.
The company ended the quarter with $62,966 in cash, restricted cash and short‑term investments and working capital of $162,494, but used $18,117 of free cash flow. Management guides for Fiscal 2026 net revenue above $300 million, higher adjusted gross margins than Fiscal 2025, higher adjusted EBITDA, and positive free cash flow with capital expenditures under $10,000.
Organigram held the #1 share of the Canadian recreational cannabis market as of December 2025 and is expanding internationally, supported by a $124.6 million follow‑on investment from BAT and the Jupiter Pool. However, a material weakness in internal control over financial reporting remains under remediation, and pending U.S. legislative changes could force a sale, wind‑down or restructuring of hemp‑derived THC activities by November 2026.
Organigram Global Inc. will report its first quarter fiscal 2026 results, for the period ended December 31, 2025, on Tuesday, February 10, 2026, before the market opens. The company will host a conference call that day at 8:00 a.m. Eastern Time for investors and analysts.
Participants must register online to receive personalized dial-in details and access codes, and a live webcast will also be available. A replay of the webcast will be posted on Organigram’s investor website within 24 hours and remain accessible for 90 days. The filing also reiterates the company’s cannabis-focused operations in Canada and includes standard forward-looking statement cautions.
GLOBAL INC. has set key dates for its upcoming annual and special meeting of security holders. The meeting will be held on March 30, 2026, and holders of common shares on record as of February 23, 2026 will be entitled to receive notice and vote.
The meeting will cover both regular annual business and special matters. Notice-and-access will not be used for either registered or beneficial shareholders, and the issuer will pay for delivery of proxy-related materials to objecting beneficial owners.
Organigram Global Inc., a Canadian cannabis company listed on the TSX and Nasdaq under the symbol “OGI”, filed its annual report on Form 40-F as a foreign private issuer using IFRS.
The report notes 134,461,029 common shares outstanding as of the fiscal year ended September 30, 2025 and incorporates audited consolidated financial statements, management’s discussion and analysis, and an annual information form by reference.
Management determined that the company’s disclosure controls and internal control over financial reporting were not effective as of September 30, 2025 because of material weaknesses, and the independent auditor issued an adverse opinion on the effectiveness of ICFR.
The filing outlines remediation steps completed in Q4 Fiscal 2025, including engaging internal control specialists, hiring a VP of Information Technology, dedicating resources to review third‑party service organization reports and remediating certain IT general controls, and describes the board’s independent audit, compensation, governance and investment committees, code of ethics and alignment with TSX and applicable Nasdaq corporate governance standards.